“These companies are all making important strides in next-gen solutions for COVID-19, cancer and other sectors. But remember, they’re small companies in a risky space, nibble on them and be patient,” advise the authors of today’s article in regards to the seven “A-rated” aggressive biotech stocks they highlight. For these seven biotech stocks – and whether they could be “Master Key” investments – CLICK HERE.
